#United States #CAR-T therapy #Gaithersburg #Lentiviral Vector #Vector BioMed

Vector BioMed Achieves Recognition as Leading Lentiviral Vector Manufacturer

Vector BioMed, a premier supplier and contract vector development and manufacturing organization, has been named the Lentiviral Vector Design and Manufacturing Company of the Year in Asia for 2026 by Life Sciences Review. This acknowledgment underscores the company's dedication to advancing healthcare by facilitating the development and production of CAR-T therapies closer to patients.

Commitment to Quality and Accessibility

Founded in 2023 by a group of experts responsible for the first lentiviral CAR-T therapy to reach patients, Vector BioMed has focused exclusively on lentiviral vectors, distinguishing itself from other contract manufacturers that offer a wider array of technologies. The company has provided vector development services to over 40 clients, targeting various cancers including leukemia, lymphoma, and multiple myeloma. With an emphasis on efficiency and cost reduction, Vector BioMed has developed the innovative LENTIVERSE™ platform, which streamlines the manufacturing processes for these advanced treatments.

Addressing Critical Healthcare Gaps

Vector BioMed's mission is to overcome the barriers presented by high costs, limited manufacturing infrastructure, and a lack of specialized expertise in regions such as Asia-Pacific. By facilitating local manufacturing of cell therapies, the company effectively shortens the distance between treatment facilities and patients, thereby increasing access to revolutionary therapies. For instance, in India, Vector BioMed has partnered with Muni Seva Ashram in Vadodara to expand access to CAR-T therapy for economically disadvantaged patients.

Proximity to Treatment

Michael Kadan, COO of Vector BioMed, emphasizes the importance of proximity in healthcare delivery: "Proximity to treatment is the primary factor in determining who gets treated." By supporting local healthcare providers in establishing manufacturing capabilities, Vector BioMed ensures that patients have better access to life-saving therapies. The company’s collaborative efforts enable healthcare teams to manufacture cell therapies consistently and sustainably, supported by direct access to lentiviral vector scientists who impart essential expertise.

Innovative Solutions for Manufacturing

Vector BioMed's LENTIVERSE™ platform offers tailored solutions to suit existing healthcare workflows. The company’s LaunchSuite provides ready-to-deploy lentiviral vectors along with comprehensive documentation and standardized manufacturing procedures for CAR-T targets. This enables local teams to initiate treatment seamlessly within their facilities. Additionally, the VectorCraft service allows for custom lentiviral vector development tailored for earlier-stage therapies, expediting the journey from gene sequence to GMP-manufactured vector within a year.

Global Impact and Recognition

The recognition from Life Sciences Review is the result of a rigorous evaluation process that included nominations from subscribers and an assessment by an editorial advisory board composed of industry experts. This accolade not only showcases the specialized expertise of Vector BioMed but also highlights its commitment to enhancing patient access to complex therapies. The strategic partnerships and initiatives with healthcare providers across the Asia-Pacific have positioned Vector BioMed as a crucial player in the biotech landscape.

Conclusion

As Vector BioMed continues to forge ahead in the realm of lentiviral vector manufacturing, the company's goal remains clear: to make advanced cell and gene therapies accessible to patients globally. By equipping local healthcare teams with the right tools, processes, and scientific know-how, Vector BioMed endeavors to reshape the delivery of crucial therapies and improve patient outcomes significantly.

For more information regarding Vector BioMed's services and its recent award, you can visit Life Sciences Review.